About Us

About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eradivir’s EV25 Shows Promising Results in Phase 2a Trial for the Treatment of Influenza

By: via Business Wire

Study Demonstrates EV25’s Safety, Tolerability and Efficacy in Reducing Viral Load and Symptoms

Eradivir Inc., a clinical-stage biotechnology company that targets the power of the immune system to treat disease, today announced the successful completion of its Phase 2a clinical trial for EV25, a therapy for the treatment of influenza. The study demonstrated that EV25 is safe, well-tolerated and significantly reduces viral loads and influenza symptoms, paving the way for a larger Phase 2b trial.

The First-In-Human (FIH), Phase I/2a, placebo-controlled, randomized, double-blind, single-center, single ascending dose (SAD) study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of EV25. The study consisted of two parts: Part 1 involved healthy adult participants, and Part 2 involved healthy adult participants inoculated with an attenuated H3N2 influenza virus. Key findings included:

  • FLU-PRO© Symptom Score Reduction: Treatment with a single 300 mg dose of EV25 demonstrated a significant reduction in total influenza symptom duration and severity as measured by AUC of FLU-PRO total scores, as well as a significant impact on peak total score and body/systemic scores. It also demonstrated a significant decrease in the number of participants with lower respiratory tract infection (35.7% in 300 mg EV25 vs 85.7% in the placebo group, p=0.0065), and a decrease in body/systemic symptom severity.
  • Reduction in Viral Loads: A 300 mg single dose of EV25 significantly decreased the amount of infectious and total attenuated H3N2 influenza virus, with a 98% decrease in median viral load AUC compared to placebo. This large difference occurred early in the disease time course, suggesting EV25 has a rapid impact on the disease.
  • Safety and Tolerability: EV25 was generally safe and well-tolerated with no dose dependent safety trends.
  • Pharmacokinetics: EV25 was quickly absorbed via a liquid intranasal spray. The exposures were linear between doses and well predicted by preclinical models. The PK profiles measured are supportive of a single dose therapy for treating influenza.

“We are thrilled that the Phase 2a results showed that EV25 was well tolerated and demonstrated significant reduction in both viral loads and influenza symptoms,” said Martin Low, Eradivir Chief Executive Officer. “These results are encouraging and support the continued development of EV25 as a potential treatment for influenza. We look forward to advancing EV25 into a larger Phase 2b trial to further evaluate its efficacy.”

Eradivir will conduct EV25’s Phase 2b study in both the United States and Europe in conjunction with the 2026-2027 influenza season. This larger study is expected to include up to 375 participants and further evaluate EV25’s efficacy and dosing.

EV25 was built on Eradivir’s BAiT (Bispecific Antigenic immuno-Therapy) platform that combines the simplicity of small molecules with the efficacy of antibodies. Eradivir’s technology recruits endogenous antibodies to target virus and infected cells to clear the disease. By altering the targeting portion of the molecule, the platform can be leveraged to treat a myriad of diseases.

In addition to EV25, the company is currently evaluating other candidates for the treatments of Respiratory Syncytial Virus (RSV), and Dengue Fever.

ABOUT ERADIVIR

Eradivir Inc. is a privately held, clinical-stage biotechnology company that focuses the power of the immune system to treat viral infections and other diseases. Its proprietary BAiT platform (Bispecific Antigenic immuno-Therapy) combines the simplicity of small molecule therapies with the efficacy of antibody therapies to facilitate rapid and selective diseased cell destruction. Eradivir’s lead antiviral therapeutic EV25 recently completed a successful Phase 2a study and will enter a Phase 2b study in the Fall of 2026. Eradivir’s second drug EV148, a therapy for RSV, is planned for entry into the clinic at the end of 2026. For more information about the company and its latest news, visit www.eradivir.com.

The Phase 2a results showed that EV25 was well tolerated and demonstrated significant reduction in both viral loads and influenza symptoms.

Contacts

More News

View More
AppLovin Drops 14%: Should Investors Worry About SEC Probe?
Via MarketBeat
Topics Regulatory Compliance
Tickers AAPL APP META SPOT
From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift
Via MarketBeat
Topics Artificial Intelligence Energy
Tickers ASX:RUL CAT
Advanced Micro Devices Eyes $300 as AI Demand Surges
Via MarketBeat
Topics Artificial Intelligence
Tickers AMD AMZN GOOGL MSFT NVDA ORCL
Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects
Via MarketBeat
Tickers AMD NVDA QCOM
3 Rare Earth Stocks Powering America’s Critical Minerals Boom
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers CRML LAC MP
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.